NCT01717183
Unknown
Not Applicable
Assessment of the Efficacy and Safety of a New Wound Dressing in the Local Treatment of Diabetic Foot Ulcers: a Prospective, Randomised, Controlled, Double-blind, European Multicentre Clinical Trial
ConditionsDiabetic Foot Ulcer(s)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Diabetic Foot Ulcer(s)
- Sponsor
- Laboratoires URGO
- Primary Endpoint
- Percentage of complete wound closure
- Last Updated
- 12 years ago
Overview
Brief Summary
The main purpose of this trial is to demonstrate that the new dressing is more effective than the current dressing in the local treatment of chronic foot ulcers in diabetic patients.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male or female over 18 years old who has provided his/her written informed consent
- •Patient covered by the French national insurance system
- •Patient with Type 1 or Type 2 diabetes mellitus with glycated hemoglobi(HbA1c) levels ≤ 10% (assayed in the previous 3 months. If not available, this assay must be performed during the run-in period)
- •Inpatient or outpatient who can be monitored by the same investigating team throughout the duration of the study
- •Patient who agrees to wear the prescribed off-loading system every day, associated with the test dressing
- •DFU with adequate arterial blood supply in the target limb DFU grade I-C or II-C as defined by the University of Texas Diabetic Wound Classification
- •Neuropathy confirmed by loss of protective sensation to monofilament test (Semmes-Weinstein 5.07 monofilament)
- •DFU located on the toe or on the lateral, dorsal or plantar side of the foot
- •Target DFU surface area between 1 cm² and 30 cm², following debridement DFU duration between 1 and 24 months
- •No local clinical infection (as defined by IDSA/IWGDF criteria) for any wound (target DFU or not) on lower limbs
Exclusion Criteria
- •Pregnant or breast-feeding woman or woman of childbearing potential not using effective means of contraception
- •Patient who took part in another clinical trial in the previous month or who is to take part in another clinical trial in the 20 weeks following inclusion
- •Patient with any known intolerance or allergy or reported adverse reaction to one of the components of the trial dressings
- •Patient who has undergone surgery or surgical revascularization (vascular reconstruction or angioplasty) in the previous 2 months
- •Patient who has presented an acute ischemic event (Acute Myocardial Infarction (AMI) or stroke) in the 3 months before inclusion
- •Patient with Severe kidney failure, defined as requirement for dialysis
- •Patient with a systemic infection not controlled by suitable antibiotic treatment
- •Patient with known osteomyelitis
- •Patient with leg ulcer(s), regardless of limb
- •Patient with wounds other than the target DFU located on the heel or on the interdigital part of the foot
Outcomes
Primary Outcomes
Percentage of complete wound closure
Secondary Outcomes
- Time to complete wound closure
- Change in wound surface area
Similar Trials
Terminated
Not Applicable
A Clinical Study of An Antimicrobial Gauze DressingWoundsNCT00203489Tyco Healthcare Group200
Unknown
Not Applicable
Efficacy and Safety of a New Compression System URGO BD001 in the Treatment of VLU (FREEDOM)Venous Leg UlcerNCT04613687Laboratoires URGO52
Recruiting
Not Applicable
Evaluation of the Efficacy of a New Specific Infant Formula in Case of Functional ConstipationFunctional ConstipationNCT05340712United Pharmaceuticals80
Completed
Phase 3
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate CancerMetastatic Castration-resistant Prostate CancerMetastatic Castration-sensitive Prostate CancerMetastatic Prostate CancerNCT04887506Tavanta Therapeutics107
Recruiting
Not Applicable
Assessment of efficacy and safety for a new wound dressing URGO 310 3166 in the local treatment of venous or mixed leg ulcers: a european, randomised clinical trialleg ulcersDRKS00009329aboratoires URGO220